Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

PHASE3CompletedINTERVENTIONAL
Enrollment

144,000

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
Leprosy
Interventions
DRUG

Rifampicin

Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.

Trial Locations (3)

Unknown

Damien Foundation, Anjouan

Damien Foundation, Mohéli

Fondation Raoul Follereau, Miandrivazo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Damien Foundation

OTHER

collaborator

Centre d'Infectiologie Charles Mérieux

OTHER

collaborator

Fondation Raoul Follereau

UNKNOWN

collaborator

Leiden University Medical Center

OTHER

collaborator

L'Institut National de la Santé et de la Recherche Médicale

UNKNOWN

collaborator

Genoscreen

OTHER

collaborator

Instituto Fernandes Figueira

OTHER_GOV

lead

Institute of Tropical Medicine, Belgium

OTHER